Nephrology
1 drug is in development for Hypothalamic Obesity.
- Companies
- 1
- Clinical trials
- 5
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hypothalamic Obesity pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| LB54640 | RHYTHM PHARMACEUTICALS, INC. (RYTM) |
About this indication
Hypothalamic Obesity context
Nephrology·MeSH: Sexual Infantilism (D050035)
Prevalence
42000.0 / 100K
Incidence
2000.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Hypothalamic Obesity?
BioSniper tracks 1 drug in development for Hypothalamic Obesity across 1 company.
How many clinical trials target Hypothalamic Obesity?
There are 5 clinical trials targeting Hypothalamic Obesity tracked by BioSniper.
What is the prevalence of Hypothalamic Obesity?
The estimated prevalence of Hypothalamic Obesity is approximately 42000.0 per 100,000 population.